1. 794 Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors. (10th December 2020) Authors: Moreno, Victor; Gaudy-Marqueste, Caroline; Wermke, Martin; Italiano, Antoine; Romano, Emanuela; Marabelle, Aurelien; Connors, Emilee; Zhou, Heng; Dobrenkov, Konstantin; Chartash, Elliot; Calvo, Emiliano; Aller, Emiliano Calvo Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A474 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗